Canada ups COVID-19 vaccine order from Novavax to 76M doses

By The Science Advisory Board staff writers

January 25, 2021 -- Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19 vaccine.

Canada has already committed to purchase 52 million doses of the vaccine and has executed its option for up to an additional 24 million doses.

NVX-CoV2373 is currently in phase III clinical development for the prevention of COVID-19. The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency. Novavax also expects to announce initial phase III efficacy results as early as the first quarter of 2021.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.